Doccol Corporation is honored to collaborate with the Stroke Pre-Clinical Assessment Network (SPAN) to push the boundaries of stroke treatment research. SPAN conducts cutting-edge, late-stage preclinical studies on cerebroprotective therapies, rigorously testing them alongside reperfusion treatments like thrombolysis and thrombectomy. Using Doccol’s high-quality, precision-engineered sutures and microcatheters, SPAN achieves consistent, reliable, and reproducible results that help identify promising interventions to extend treatment windows and improve outcomes for stroke patients. Together, this partnership is setting new standards in preclinical stroke research.

SPAN was established to address a significant need in the scientific investigation of stroke treatment. In the past, a plethora of putative neuroprotectants proceeded to clinical trial based on favorable preclinical assessment, only to fail in subsequent clinical trials of human stroke patients. The recent successful development of thrombectomy for acute ischemic stroke generated considerable enthusiasm for re-testing treatment candidates in combination with thrombectomy. Thus, SPAN is intended to screen and select highly promising treatment candidates for possible further study in human clinical trials. 

The SPAN Coordinating Center plays a vital role in organizing the efforts of all participating centers, ensuring alignment on shared goals, values, and standards.

The SPAN 2.0 network includes the following institutes:

Yale University

Massachusetts General Hospital (MGH)

The Medical College of Georgia (MCG) at Augusta University

University of Iowa

Duke University

University of California San Diego (UCSD)

For more information about the SPAN Network, please visit www.spannetwork.org.